In a study of 118 patients with advanced breast cancer treated with aminoglutethimide plus hydrocortisone replacement the overall objective response rate was 42 (36%). Response was not determined either by the nature or the extent of previous treatment, including endocrine therapy and/or chemotherapy, nor by oestrogen-receptor status. The vast majority of patients who responded were postmenopausal but a complete response was seen in a premenopausal patient with skin metastases. Aminoglutethimide is useful in the second-line treatment of postmenopausal subjects with advanced breast cancer.
|Original language||English (US)|
|Number of pages||3|
|Journal||South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde|
|Publication status||Published - 1987|
ASJC Scopus subject areas